Excited to present results of this trial focused solely on Black people with breast cancer at #ASCO24 adjuvant breast session 🎬 Picture below highlights patient recruitment efforts developed with advocate extraordinaire Lisa Hayes

Important data from Grace Choong presented today to help guide management of patients with ER very low tumors. NCDB suggests omission of ET in ER 1-10% is associated with ⬆️ risk of death, esp in patients who don’t have a pCR to chemo.

Long awaited post monarch. Abema post mostly palbo improved PFS with small median but sign HR. Impact prob less in visceral Mets. In ET sensitive without targ mut and with non visceral disease a new option. #ASCO24 OncoAlert Kevin Kalinsky, MD, MS

#INAVO120 👩🏼 w/ 1) PI3 mutation AND 2)relapse within 12 months of adj ET Fulvestrant + palbo +/- inavolisib: PFS improved 7.3 to 15.0 mo Time to chemo prolonged HR 0.54 AEs include: BG 🍬, diarrhea 💩, rash, and stomatitis 😫...but discontinuations very rare #ASCO24 #bcsm

So, the 3 drug combo is really a 7 drug combo? I think it is safe to say we have farther to go to get from “Comfort to Cure” #ASCO24

Had high hopes that #breastcancer - esp #tnbc - would have benefit similar to urothelial carcinoma. -Alas, not yet. Will see what the future holds for EV in breast cancer. -Love the potential for biomarker-driven analyses as described by discussant Shanu Modi #bcsm #ASCO2024

One of the most important points I have heard at #ASCO24 so far Jill Feldman 🚫 safety is not tolerability ❤️‍🩹low grade side effects matter Julia Maués Dr. Kelly Shanahan

Thank you ASCO for fostering mentor-mentee relationships across countries! Ishka Que taught me so much about the care delivery I take for granted practicing in a well resourced country!

Check out Journal of Clinical Oncology Podcast: "EAZ171: Predictors of TIPN in Black women with #BreastCancer" w/ Dr. Shannon Westin, MD, MPH, FASCO & Dr. Bryan Schneider. EAZ171 was presented at the #ASCO24 Annual Meeting. Tarah Ballinger, MD NCI Prevention & Early Detection #NCORP Susan G. Komen Vera Bradley Foundation jcopodcast.libsyn.com/eaz171-predict…

🚨Docetaxel chemotherapy causes less peripheral neuropathy than paclitaxel chemotherapy for Black people with early-stage breast cancer Read the lay summary, read the manuscript. So important. #ASCO24 #CIPN Tarah Ballinger, MD OncoAlert

Thank you Susan G. Komen for your support!!

Very grateful for the mentorship and sponsorship I have experienced in ECOG-ACRIN Cancer Research Group thanks to Angie DeMichele, MD, MSCE, FASCO Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Lynne I Wagner PhD , providing me the opportunity to disseminate EAZ171 today at #ASCO24 📸: Yara Abdou

Congrats to wonderful colleague and leader Nabil Adra

Here are lay summaries on some of the top research presented at #ASCO24. Each summary includes: 👉Who does this study affect? 👉What did this study find? 👉What does this mean for patients? Thank you, ASCO, for your efforts to help the lay community understand all the

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy ascopost.com/videos/2024-as… #bcsm #breastcancer #oncology #healthequity Reshma Jagsi Winship Cancer Institute of Emory University Emory School of Medicine IU Simon Comprehensive Cancer Center Tarah Ballinger, MD

TREC year 8 is underway!! 23 new fellows totaling 202 TREC fellows across 78 institutions!! Amazing energy balance and cancer research! Applications open Oct for June 2025. ysph.yale.edu/trecrep/

Congratulations to Nabil Adra for leading the IU School of Medicine IU School of Medicine Department of Medicine Division of Hematology-Oncology 2024 ASCO Review. Thanks to our incredible faculty speakers who made it an informative and entertaining day!

Tune in NOW for Breast Cancer Breakthroughs! Practice-changing advancements in #breastcancer were just announced @ #ASCO24. Komen grantees Tarah Ballinger, MD & Dr. Pedram Razavi explain how these findings are personalizing treatment. Click here to watch: bit.ly/3X1yPW0

Cancer survivorship care IS cancer care. Every bit of clinical work and research done to support survivors is relevant to the cancer care plan and should be delivered in tandem with medical therapies through the cancer continuum, and with primary care follow-up beyond. From

📢 New faculty opportunity in the Division of Breast Surgery! ❗Come join the team at Indiana University School of Medicine in the Division of Breast Surgery as Assistant/Associate/Professor of Clinical Surgery - Breast Surgeon. We are seeking a fellowship-trained breast surgeon